NCT01535040View on ClinicalTrials.gov

Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking

PHASE2CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

August 1, 2012

Primary Completion Date

February 1, 2014

Study Completion Date

February 1, 2014

Conditions
Breast CancerColorectal CancerLung CancerProstate CancerTobacco Use Disorder
Interventions
DRUG

memantine hydrochloride

Estimate participation, accrual, adherence, and retention of cancer survivors who smoke and are randomized to receive memantine (10 mg twice daily) or a matching placebo for 12 weeks.

DRUG

placebo

Placebo by mouth through completion of 12 weeks.

Trial Locations (1)

27157

Wake Forest Cancer Center CCOP Research Base, Winston-Salem

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Wake Forest University Health Sciences

OTHER

NCT01535040 - Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking | Biotech Hunter | Biotech Hunter